- Home
- CREV vs OGEN Comparison
CREV vs OGEN Comparison
Compare CREV & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CREV
- OGEN
- Stock Information
- Founded
- CREV 2007
- OGEN 1996
- Country
- CREV Ireland
- OGEN United States
- Employees
- CREV N/A
- OGEN N/A
- Industry
- CREV
- OGEN Biotechnology: Pharmaceutical Preparations
- Sector
- CREV
- OGEN Health Care
- Exchange
- CREV Nasdaq
- OGEN Nasdaq
- Market Cap
- CREV 6.0M
- OGEN 5.0M
- IPO Year
- CREV N/A
- OGEN N/A
- Fundamental
- Price
- CREV $4.23
- OGEN $1.28
- Analyst Decision
- CREV
- OGEN
- Analyst Count
- CREV 0
- OGEN 0
- Target Price
- CREV N/A
- OGEN N/A
- AVG Volume (30 Days)
- CREV 30.4K
- OGEN 112.2K
- Earning Date
- CREV 05-14-2025
- OGEN 11-12-2025
- Dividend Yield
- CREV N/A
- OGEN N/A
- EPS Growth
- CREV N/A
- OGEN N/A
- EPS
- CREV N/A
- OGEN N/A
- Revenue
- CREV $39,261,077.00
- OGEN N/A
- Revenue This Year
- CREV $40.76
- OGEN N/A
- Revenue Next Year
- CREV $86.18
- OGEN N/A
- P/E Ratio
- CREV N/A
- OGEN N/A
- Revenue Growth
- CREV 41.52
- OGEN N/A
- 52 Week Low
- CREV $2.00
- OGEN $1.01
- 52 Week High
- CREV $12.75
- OGEN $18.90
- Technical
- Relative Strength Index (RSI)
- CREV 50.85
- OGEN 54.57
- Support Level
- CREV $3.92
- OGEN $1.02
- Resistance Level
- CREV $4.30
- OGEN $1.34
- Average True Range (ATR)
- CREV 0.35
- OGEN 0.07
- MACD
- CREV -0.00
- OGEN 0.05
- Stochastic Oscillator
- CREV 39.22
- OGEN 81.82
About CREV Carbon Revolution Public Limited
Carbon Revolution PLC is an Australian-based technology company manufacturing carbon fiber wheels. It is an OEM supplier and a world-wide manufacturer of lightweight technology carbon fibre wheels to the automotive industry. The Company supplies wheels to OEMs across the globe for luxury and high-performance vehicles and SUVs, and is developing wheels for electric vehicles under contract for its OEM customers. The company generates maximum revenue Internationally.
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.